Skip to main content
Figure 3 | Journal of Neuroinflammation

Figure 3

From: Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice

Figure 3

Open field test analysis of SCI mice treated centrally with anti-TNF therapy for three consecutive days and allowed 35 days of survival after SCI. (A,B) Analysis of locomotor activity in mice treated centrally with either saline, XPro1595, or etanercept and allowed 35 days survival after SCI showed that all mice travelled a similar distance (A) at comparable speeds (B) in the open field test. (C,D) Analysis of anxiety-related behavior in the open field test showed that XPro1595-treated mice displayed decreased anxiety-related behavior represented by increased center/perimeter ratio (C) and increased number of zone changes into the perimeter and center area (D). (E,F) The number of droppings (E) was comparable in all groups of mice, whereas the number of groomings was increased both in XPro1595- and etanercept-treated mice compared to saline-treated mice. *P <0.05 and **P <0.01, one-way ANOVA followed by Tukey’s test.

Back to article page